Key Highlights

  • Shares rose 6.51% to USD 10.14 on relative Volume of 2.01.
  • The FDA granted lonvo-z priority review, with a March 10, 2027 goal date.
  • HAELO showed an 87% mean attack-rate reduction from weeks 5 to 28.
  • Payer outreach covers more than 280 million U.S. lives.

Intellia (NASDAQ:NTLA) shares traded at USD 10.14 on November 20, 2026, up 6.51%, with a relative volume at time of 2.01. The company has given no reason for the heavy trading. It hosted a webcast on November 12 titled "Readying Lonvo-z for Patients with HAE" and furnished its slides in a Form 8-K, so that event predates the session.

Intellia is a Delaware company based in Cambridge, Massachusetts. It develops investigational in vivo CRISPR-based therapies for severe diseases. Its lead program, lonvoguran ziclumeran, or lonvo-z, formerly NTLA-2002, is being developed as a one-time treatment for hereditary angioedema, or HAE. It also has Phase 3 trials in transthyretin amyloidosis, covering ATTR-CM and ATTR-PN, with nexiguran ziclumeran.

Regulatory Status

The U.S. Food and Drug Administration accepted the Biologics license application for lonvo-z in HAE and granted priority review, with a goal date of March 10, 2027. In a September 3 communication, the agency said it did not currently plan an advisory committee for the application. The presentation describes lonvo-z as investigational and not yet approved by any regulator.

Phase 3 HAELO Results

The HAELO trial met its primary and all key secondary endpoints, with a data cutoff of February 10, 2026. It enrolled 52 patients on lonvo-z and 28 on placebo. The mean attack-rate reduction from weeks 5 to 28 was 87%, with a 95% confidence interval of 78% to 93% and p below 0.0001.

For attack-free status in that window, 62% of lonvo-z patients qualified versus 11% on placebo, with an odds ratio of 12.8 and an interval of 3.5 to 47.6. Among 35 of the 52 lonvo-z patients on long-term prophylaxis at entry, attack rates fell 81% after treatment.

Integrated Safety Data

The integrated analysis covers 117 patients across the Phase 1/2 and Phase 3 studies, and 93 of them received a single 50 mg dose. Follow-up reached up to four years in the earliest patients.

Of those 93 patients, 82, or 88%, had a treatment-emergent adverse event. Infusion-related reactions affected 51 patients, or 55%, headache 18, or 19%, and fatigue 17, or 18%. Two patients had Grade 3 serious events: a pulmonary embolism 12 months after infusion in a patient with multiple risk factors, and a perforated appendicitis 22 months after infusion that was not considered treatment-related.

Commercial Preparations

If the therapy is approved, Intellia has built payer account, reimbursement, strategic account, field medical, sales and patient services teams. Payer outreach began in early 2025 and covers more than 280 million U.S. lives. A network of authorized treatment centers is being prepared, with a goal of placing most patients within 100 miles of a center.

A digital campaign launched in May and reached 95% of HAE prescribers. Field engagement began in September with 1,300 priority providers who treat more than two HAE patients. After approval, the company plans to begin promotion through digital and field channels.

What to Watch Next for Intellia

The company has given no reason for the November 20 move, and its presentation came earlier. The record shows a pending regulatory decision, strong trial results with a defined safety profile and launch groundwork. The March 10, 2027 goal date is the next dated event.